A patient was diagnosed with pancreatic cancer with tumors that could not be surgically removed. The patient was given the option of standard chemotherapy using gemcitabine, or he could be placed in a new clinical trial that combined gemcitabine with a nanoparticle albumin-bound (nab)-paclitaxel. The nab-paclitaxel drug is a taxol derivative that works by altering microtubule dynamics.
How does altering microtubule dynamics affect cancer progression?